TempraMed's Strategic Expansion into the Turkish Diabetes Market

The global diabetes crisis has reached critical levels, with Turkey emerging as one of the most affected nations in Europe. According to projections, Turkey's diabetes prevalence is projected to reach 31.5% among adults, driven by soaring obesity rates and sedentary lifestyles. This represents a significant market opportunity for companies like TempraMed, which is leveraging exclusive distribution partnerships to scale profitability in high-prevalence regions. By securing a strategic foothold in Turkey-a country with 10 million diabetics and a rapidly growing demand for temperature-sensitive therapies-TempraMed is positioning itself to capitalize on both medical necessity and market dynamics.

A High-Stakes Market: Diabetes in Turkey

Turkey's diabetes epidemic is among the most severe in the European region. According to the International Diabetes Federation, the country's age-standardized diabetes prevalence in adults aged 20–79 was 14.5% in 2025, while modeling studies project a staggering 31.5% prevalence by year-end. These figures are exacerbated by Turkey's 66.8% overweight and obesity rate-the highest in Europe according to WHO data. The aging population and rising adoption of Westernized diets further compound the challenge, creating a fertile ground for diabetes-related innovations.

The economic and healthcare burden is immense. With approximately 1 million insulin users in Turkey, the demand for temperature-stabilizing solutions is acute. Insulin and GLP-1 therapies, which require precise storage conditions, are particularly vulnerable to environmental degradation. TempraMed's patented temperature-controlled storage technology addresses this unmet need, offering a value proposition that aligns with both patient outcomes and healthcare system efficiency.

Strategic Partnerships: Scaling Profitability Through Distribution

TempraMed's expansion into Turkey is anchored by an exclusive distribution agreement with Dolfin Sağlık Ürünleri, a leading medical device distributor with deep institutional ties. This partnership, announced in December 2025, marks a pivotal shift from TempraMed's earlier direct-to-consumer (B2C) model to a B2B and retail-focused strategy. By integrating its "VIVI" line of temperature-stabilizing products into Dolfin's network-which spans hospitals, pharmacies, and insurers-TempraMed is reducing patient acquisition costs while expanding access to critical therapies.

The financial rationale is compelling. Dolfin's established relationships with healthcare providers and payers enable TempraMed to bypass the high costs of digital marketing and direct sales. Instead, the company is embedding its solutions into standard-of-care protocols, particularly for insulin-dependent patients and GLP-1 therapy users. This approach creates recurring revenue streams through institutional contracts.

The GLP-1 Opportunity: A $35 Billion Market in 2025

The global GLP-1 (glucagon-like peptide-1) agonist market is a key growth driver for TempraMed's Turkish expansion. In 2025, the GLP-1 diabetes treatment drugs market was valued at USD 6,556.5 million, with projections of USD 62,543.2 million by 2035-a compound annual growth rate (CAGR) of 25.3%. Turkey's diabetes population, coupled with its high obesity rates, positions the country as a prime market for these therapies, which are increasingly prescribed for both glycemic control and weight management.

TempraMed's temperature-stabilizing solutions are uniquely suited to this segment. GLP-1 therapies, like insulin, require precise storage conditions to maintain efficacy. By ensuring these medications remain viable in diverse environments, TempraMed's technology enhances treatment adherence and reduces waste-a critical factor in markets with limited healthcare infrastructure.

Conclusion: A Calculated Bet on a High-Prevalence Market

TempraMed's entry into Turkey exemplifies a strategic, data-driven approach to scaling profitability in high-prevalence diabetes markets. By partnering with Dolfin Sağlık, the company is leveraging existing distribution networks to reduce costs, accelerate adoption, and align with institutional healthcare needs. Meanwhile, the explosive growth of the GLP-1 market-projected to surpass $100 billion by 2033-provides a long-term revenue tailwind.

For investors, the case is clear: TempraMed is not merely selling a product but addressing a systemic healthcare challenge in a market where demand is both urgent and underserved. As Turkey's diabetes rates continue to climb, the company's ability to integrate its technology into standard care pathways will determine its success-and potentially redefine its role in the global diabetes ecosystem.